What Connext does

Connext (코넥스트) is a privately held, clinical-stage South Korean biopharmaceutical company founded in October 2017 as a concurrent startup out of the Korea Institute of Industrial Technology (KITECH), where the founding technology in recombinant collagenase and recombinant TLR5 agonists was developed. The company operates two proprietary platform technologies built on microbial (E. coli) recombinant protein expression: a recombinant collagenase platform (lead asset CNT201; follow-on CNT202 for burn necrotic tissue removal) and a recombinant TLR5 agonist platform (CNT101/xempritolimod for acute graft-versus-host disease and acute radiation syndrome; CNT102 for immuno-oncology). Its lead asset, CNT201, is positioned as the world's first recombinant collagenase therapeutic, eliminating the hemolytic toxin contamination risk associated with the only existing approved competitor (Xiaflex) and offered in a differentiated single-vial lyophilized formulation that reconstitutes with standard water for injection.

Connext addresses unmet need across three indications with CNT201 — Dupuytren's contracture (lead indication, currently in Phase 2 in Australia), Peyronie's disease, and cellulite — and pursues a defensible "Best-in-Class" novel biologic positioning (not biosimilar) that the company asserts supports a 12-year market exclusivity path. The R&D and manufacturing backbone is an ISO 9001-certified 50L-scale pilot facility at the Daegu-Gyeongbuk Advanced Medical Complex with upstream fermenter capacity and downstream purification equipment (continuous centrifuge, ultrafiltration, pilot column controller), enabling in-house GMP manufacturing for clinical supply and future commercial product sales.

The business model is a hybrid of (1) licensing and collaboration deals with global pharmaceutical companies for CNT101 and CNT201, structured as upfront payments plus development milestones (Phase 1 through BLA submission and approval) plus ongoing royalties and sales milestones; (2) retained manufacturing and supply of finished drug product to licensing partners rather than pure technology transfer; (3) CDMO services for recombinant proteins and mRNA vaccine pDNA; and (4) direct sales of GMP-grade tissue-dissolving enzyme products (TDzyme) for research and industrial use. The customer base is exclusively B2B: global pharma licensing partners, biotech CDMO clients, and research/industrial enzyme buyers. As of early 2026 the company had not generated commercial product revenue and is funded by approximately 33.8 billion KRW (~$24–25M USD) of cumulative venture capital from Korean VCs plus a strategic investor (PharmaResearch), with a KOSDAQ technology-specialty listing targeted for 2027.

Name

Connext

Legal name

CONNEXT Co., Ltd.

Website

https://connext.co.kr

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Connext is a clinical-stage South Korean biopharmaceutical company developing recombinant protein therapeutics using microbial E. coli expression. Its lead candidate CNT201 (recombinant collagenase) targets Dupuytren's contracture, Peyronie's disease, and cellulite, while its TLR5 agonist platform addresses immuno-oncology and acute graft-versus-host disease.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

akta.pro secondary industries

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Recombinant protein therapeutics
• Biopharmaceutical drug development
• Collagenase enzyme therapy
• TLR5 agonist immunomodulator
• CDMO contract manufacturing

Headquarters

HQ city

Daegu

HQ country

South Korea

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing and Collaboration Deals: Connext enters into licensing deals (for CNT101) and collaboration deals (for CNT201) with overseas pharmaceutical companies for co-development and market entry. Revenue is generated through upfront payments, development milestone payments tied to clinical phases (Phase 1 through Phase 3, BLA submission, and approval), and ongoing royalties based on yearly sales plus sales milestone payments.
2. Product Sales (Finished Pharmaceuticals): Leveraging its GMP manufacturing facility, Connext manufactures and sells finished pharmaceutical products directly. The company retains manufacturing and supply roles in global partnerships, enabling product revenue beyond simple technology transfer.
3. CDMO Services: Contract development and manufacturing services for recombinant protein therapeutics and mRNA vaccine plasmid. Services include process development, scale-up, non-clinical sample manufacturing, and quality analysis for external biotech and pharma companies. Positioned as a bio-material/bio-parts revenue stream.
4. Biomaterial Product Sales (TDzyme): Sale of GMP-grade tissue-dissolving enzyme products (TDzyme) for research and industrial applications.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Connext is a clinical-stage biopharmaceutical company that develops and manufactures recombinant protein therapeutics using a genetically engineered E. coli expression platform. Its core offerings are the recombinant collagenase candidate CNT201 for Dupuytren's contracture, Peyronie's disease, and cellulite, and the recombinant TLR5 agonist candidate CNT101 (xempritolimod) for acute graft-versus-host disease and acute radiation syndrome. The company also offers CDMO services for recombinant protein and pDNA manufacturing and sells a GMP-grade tissue-dissolving enzyme (TDzyme).

Product overview

Connext is a clinical-stage biopharmaceutical company developing recombinant protein-based therapeutics using two platform technologies: recombinant TLR5 agonists (CNT101, CNT102) and recombinant collagenase (CNT201, CNT202). The lead product CNT201 targets Dupuytren's contracture, Peyronie's disease, and cellulite, while CNT101 addresses acute graft-versus-host disease. The company also commercializes tissue-dissolving enzyme products (TDzyme) and provides CDMO services for recombinant protein and pDNA manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

• CNT201

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• PharmaResearch (파마리서치)coreStrategic or Co-development Partner · 1 March 2026PharmaResearch, a regenerative medicine company, entered into both a strategic equity investment and a licensing/supply agreement for CNT201 for the aesthetic indication (cellulite). The partnership combines Connext's recombinant protein technology and GMP manufacturing capability with PharmaResearch's global commercialization network and aesthetic medicine expertise. Connext is responsible for clinical development and manufacturing of CNT201, while PharmaResearch leads commercialization in the aesthetic field and leverages its global network for market expansion. The partnership also includes plans for open innovation and joint development of next-generation protein-based biopharmaceuticals.
• 이연제약 (Y-Young Pharmaceutical)minorStrategic or Co-development Partner · 1 December 2022Connext signed an MOU with Y-Young Pharmaceutical for strengthening bio-pharmaceutical CDMO business. The partnership was intended to enhance Connext's contract development and manufacturing capabilities for biologics.
• 가톨릭대학교 / 서울성모병원 (The Catholic University of Korea / Seoul St. Mary's Hospital)minorStrategic or Co-development Partner · 1 January 2022Connext entered into a technology licensing agreement with The Catholic University of Korea in 2020. Additionally, the company conducted R&D collaboration with Seoul St. Mary's Hospital, including a First-in-Human clinical trial for CNT101 (xempritolimod) in healthy adults at Samsung Seoul Hospital, and conducted bridging studies for CNT101 as a treatment for acute graft-versus-host disease at The Catholic University of Korea Seoul St. Mary's Hospital.
• 분당서울대학교병원 K-바이오헬스 지역센터 (Bundang Seoul National University Hospital K-Bio Health Regional Center)minorStrategic or Co-development Partner · 1 January 2022Connext was selected for the K-Bio Health Regional Center support program in April 2022. The program provided clinical mentoring, clinical protocol development, and clinical trial support for CNT201's global clinical development. This support contributed to successful FDA pre-IND meetings and IND approval for the CNT201 Phase 1/2 clinical trial.
• 한국생산기술연구원과 겸직창업 (Korea Institute of Industrial Technology, KIIT)minorStrategic or Co-development Partner · 1 January 2022Connext was established through a concurrent entrepreneurship (겸직창업) arrangement with the Korea Institute of Industrial Technology (KIIT) in October 2017. CEO Lee Woo-jong served as Center Head of KIIT's Biomedical Production Technology Center before founding Connext, contributing recombinant collagenase and TLR5 agonist technology developed at the institute.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Others

• PharmaResearch Products: PharmaResearch is Connext's strategic investor and licensing partner for CNT201 in cellulite, and is itself a regenerative-medicine specialty pharma. Included as a direct ecosystem counterpart whose commercial uptake of CNT201 directly affects Connext's economics.

Direct peers

• Endo International: Endo markets Xiaflex (collagenase clostridium histolyticum), the only approved collagenase for Dupuytren's contracture and Peyronie's disease — the direct incumbent competitor to Connext's CNT201 in the lead indication.
• MediWound: MediWound develops enzymatic debridement therapeutics (e.g., NexoBrid) for burn and wound care, closely mirroring Connext's CNT202 burn necrotic tissue removal program. Both companies focus on enzyme-based biologics for tissue-dissolving indications.
• Anika Therapeutics: Anika commercializes hyaluronic acid-based and enzyme-based injectable therapeutics for joint health and orthopedic indications. It shares with Connext the recombinant/injectable biologics platform focus and US/EU commercialization footprint.
• Halozyme Therapeutics: Halozyme develops recombinant human hyaluronidase and other enzyme-based biologic therapeutics using proprietary platform technology. Like Connext, it leverages recombinant enzyme/protein engineering for injectable therapeutics and pursues licensing and co-development with major pharma — the closest comparable by platform and business model.

Broad incumbents

• Swedish Orphan Biovitrum (Sobi): Sobi is a European specialty biopharma with established commercialization infrastructure in rare disease and specialty injectable therapeutics, comparable as a potential global commercialization partner/competitor for niche biologics like CNT201.
• Ipsen: Ipsen has held collagenase commercial rights in select territories and operates broadly in specialty care including injectables for musculoskeletal and urological conditions — adjacent as a larger incumbent with overlapping therapeutic categories.

Emerging players

• Codiak BioSciences: Codiak developed engineered exosome-based immunomodulatory therapeutics, conceptually comparable to Connext's TLR5 agonist platform (CNT101/CNT102) in targeting innate immune pathways for oncology and inflammatory indications.
• Revance Therapeutics: Revance develops innovative injectable therapeutics (e.g., DaxibotulinumtoxinA) for aesthetic and therapeutic indications, directly comparable in the cellulite/aesthetics overlap with Connext's CNT201 cellulite program pursued via PharmaResearch.

Regional players

• Hugel: Hugel is a Korean specialty biopharma focused on aesthetics and therapeutic injectables (e.g., botulinum toxin, dermal fillers). Comparable as a Korean-listed peer operating in overlapping injectable biologics/aesthetic categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/CONNEXTBIO
• LinkedInlinkedin.com/company/connextbio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Connext